Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities

被引：0
|
作者：
Rosenkranz, S. [1 ]
Channick, R. [2 ]
Chin, K. [3 ]
Jenner, B. [4 ]
Gaine, S. [5 ]
Galie, N. [6 ]
Ghofrani, H. A. [7 ,8 ,9 ,10 ]
Hoeper, M. M. [9 ,11 ]
McLaughlin, V. V. [12 ]
Preiss, R. [4 ]
Rubin, L. J. [13 ]
Simonneau, G. [14 ]
Sitbon, O. [14 ]
Tapson, V. [15 ]
Lang, I. M. [16 ]
机构：
[1] Univ Cologne, Cologne, Germany
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] UT Southwestern Med Ctr, Dallas, TX USA
[4] Actel Pharmaceut Ltd, Allschwil, Switzerland
[5] Mater Misericordiae Univ Hosp, Dublin, Ireland
[6] Univ Bologna, Dept Expt Diagnost & Specialty Med DIMES, Bologna, Italy
[7] Univ Giessen, Giessen, Germany
[8] Marburg Lung Ctr, Giessen, Germany
[9] German Ctr Lung Res, Hannover, Germany
[10] Imperial Coll London, Dept Med, London, England
[11] Hannover Med Sch, Dept Resp Med, Hannover, Germany
[12] Univ Michigan, Ann Arbor, MI 48109 USA
[13] Univ Calif San Diego, Div Pulm & Crit Care Med, San Diego, CA 92103 USA
[14] Univ Paris Sud, Hop Univ Bicetre, Le Kremlin Bicetre, France
[15] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[16] Med Univ Vienna, Div Cardiol, Vienna, Austria
来源：
EUROPEAN HEART JOURNAL | 2019年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4973
引用
收藏
页码：3038 / 3038
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities
    Rosenkranz, S.
    Channick, R.
    Chin, K.
    Jenner, B.
    Gaine, S.
    Galie, N.
    Ghofrani, H. A.
    Hoeper, M. M.
    McLaughlin, V
    Preiss, R.
    Rubin, L.
    Simonneau, G.
    Sitbon, O.
    Tapson, V
    Lang, I
    PNEUMOLOGIE, 2020, 74 : S62 - S63
  • [2] EFFICACY OF ORAL TREPROSTINIL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION WITH AND WITHOUT CARDIOVASCULAR COMORBIDITIES
    Elwing, Jean M.
    Vizza, Carmine Dar
    Franco, Veronica
    Pepke-Zaba, Joanna
    Kim, Hyoshin
    Seaman, Scott
    Rao, Youlan
    Broderick, Meredith
    White, R. James
    CHEST, 2023, 164 (04) : 5883A - 5885A
  • [3] Safety and efficacy of sitaxsentan in elderly patients with Pulmonary Arterial Hypertension (PAH)
    Vachiery, J. L.
    Sandoval-Zarate, J.
    Keogh, A.
    Kramer, M. R.
    Barst, R. J.
    Naeije, R.
    EUROPEAN HEART JOURNAL, 2006, 27 : 623 - 623
  • [4] Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH)
    Channick, Richard
    Chin, Kelly
    Di Scala, Lilla
    Frey, Aline
    Preiss, Ralph
    Gaine, Sean
    Galie, Nazzareno
    Ghofrani, Hossein Ardeschir
    Hoeper, Marius
    Lang, Irene
    McLaughlin, Vallerie
    Rubin, Lewis
    Simonneau, Gerald
    Sitbon, Olivier
    Tapson, Victor
    CHEST, 2015, 148 (04)
  • [5] Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension
    Bruderer, Shirin
    Hurst, Noemie
    Remenova, Tatiana
    Dingemanse, Jasper
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (06) : 743 - 751
  • [6] Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag
    Tsang, Yuen
    Singh, Risho
    Verma, Sumit
    Panjabi, Sumeet
    RHEUMATOLOGY AND THERAPY, 2023, 10 (03) : 741 - 756
  • [7] Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag
    Yuen Tsang
    Risho Singh
    Sumit Verma
    Sumeet Panjabi
    Rheumatology and Therapy, 2023, 10 : 741 - 756
  • [8] Safety, Tolerability and Pharmacokinetics Study in Patients with Pulmonary Arterial Hypertension (PAH) Temporarily Switching from Oral to IV Selexipag
    Klose, H.
    Chin, K.
    Ewert, R.
    Gall, H.
    Parambil, J.
    Poch, D.
    Seyfarth, H.
    Axelsen, L.
    Schmitz, S. Hsu
    Stein, C.
    Preston, I.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (04): : S490 - S490
  • [9] Safety concerns regarding selexipag in pulmonary arterial hypertension
    Greene, Rebecca A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (07) : 419 - 420
  • [10] BUDGET-IMPACT OF SELEXIPAG FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Bilir, S. P.
    Beaudet, A.
    Zervoudaki, A.
    Lamprou, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2017, 20 (09) : A641 - A642
12345